By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Relmada Therapeutics 



  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS








Company News
Relmada Therapeutics Receives Health Canada Clearance To Commence First Clinical Study For Novel Oral Formulations Of Buprenorphine 3/24/2015 6:56:06 AM
Relmada Therapeutics Reports Positive Phase 1 Results For NMDA Receptor Antagonist D-Methadone 3/17/2015 6:42:46 AM
Relmada Therapeutics To Present At Future Leaders In The Biotech Industry Conference 3/12/2015 11:13:24 AM
Relmada Therapeutics Names Leading Clinicians And Researchers In Pain Therapy Development To Advisory Roles 3/5/2015 9:19:32 AM
Relmada Therapeutics To Present At ROTH Capital Partners 27th Annual Growth Stock Conference 3/3/2015 10:38:18 AM
Relmada Therapeutics Announces Filing Of Clinical Trial Application In Canada For Novel Oral Formulations Of Buprenorphine 2/24/2015 6:31:13 AM
Relmada Therapeutics To Present At The 17th Annual BIO CEO & Investor Conference 2/9/2015 11:52:09 AM
Relmada Therapeutics Selects MepiGel Formulations To Advance Into Clinical Studies 2/4/2015 8:52:22 AM
Relmada Therapeutics To Present At 11th Annual Noble Financial Capital Markets Equity Conference 1/16/2015 9:53:53 AM
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015 9:37:49 AM
1234
//-->